eagle1462010
Diamond Member
- May 17, 2013
- 69,319
- 34,352
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical...
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform. Tonix is developing TNX-801 (live horsepox virus vaccine for percutaneous administration) as a potential smallpox preventing vaccine for the U.S. strategic national stockpile and as a monkeypox preventing vaccine. The Company believes that its proprietary horsepox virus has the potential to serve as a vector for vaccines to protect against other infectious agents. The new research collaboration will develop and test a potential horsepox vaccine that expresses protein from the virus that causes COVID to protect against the disease.
![southernresearch.org](https://southernresearch.org/app/uploads//Coronavirus.jpg)
Southern Research, Tonix team to develop potential vaccine against new coronavirus - Southern Research
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, to support the development of a vaccine, TNX-1800, against the new coronavirus disease, COVID-19, based on...
![southernresearch.org](https://southernresearch.org/app/uploads/2022/06/favicon-150x150.png)
![www.madeinalabama.com](/proxy.php?image=http%3A%2F%2Fwww.madeinalabama.com%2Fassets%2F2020%2F03%2FCOVIDresearch2.jpg&hash=4a53c4ae208e1fd84f5d8986d275847b&return_error=1)
UAB teams with biotech firm to test potential COVID-19 vaccine
UAB is launching a collaboration with biopharmaceutical firm Altimmune for preclinical testing a potential vaccine to prevent COVID-19 disease.
![www.madeinalabama.com](https://www.madeinalabama.com/images/icons/favicon.png)
The testing at UAB will investigate immune responses to the vaccine in mice — a key step before Altimmune can launch a Phase 1 human trial in patients in the fall of this year.
The COVID-19 vaccine, called AdCOVID, is a single-dose vaccine candidate delivered by a nasal spray.
Gaithersburg, Maryland-based Altimmune has significant experience in the development of intranasal vaccine candidates for respiratory pathogens, including a seasonal and pandemic influenza vaccine and a vaccine for inhalation anthrax.
Human trials this fall.